Copyright
©The Author(s) 2023.
World J Meta-Anal. Jun 18, 2023; 11(5): 181-195
Published online Jun 18, 2023. doi: 10.13105/wjma.v11.i5.181
Published online Jun 18, 2023. doi: 10.13105/wjma.v11.i5.181
Ref. | Journal | Country | Study designs | Study analysis time | Objective |
Kim et al[15], 2021 | British Journal of Haematology | Korea | Retrospective | 2009-2020 | To analyze genetic abnormalities in JMML to evaluate the genetic profile of this rare paediatric leukaemia in a single Korean institution |
Hong et al[16], 2022 | Transplan tation and Cellular Therapy | Korea | Retrospective comparative | 2013-2020 | To compare outcomes in children and adolescents with high-risk acute leukemia after a busulfan-based myeloablative conditioning regimen along with HRD HSCT with PT-Cy or MUD HSCT |
Bertaina et al[17], 2018 | Blood | Italy | Retrospective | 2010-2015 | To report the outcome of children with acute leukemia who received either UD-HSCT or αβhaplo-HSCT |
Bai et al[18], 2020 | Leukemia Research | China | Retrospective | 2008-2018 | To investigate the clinical characteristics, outcomes, and effects of HSCT (especially haplo-HSCT) among non- infant children with t(v;11q23)/MLL-r B-ALL |
Ruggeri et al[19], 2021 | Transplan tation and Cellular Therapy | Italy | Prospective cohort | 2011-2019 | To analyze the outcomes of unmanipulated haploidentical Transplantation using PT-Cy in pediatric patients with acute lymphoblastic leukemia |
Sun et al[20], 2015 | European Review for Medi cal Pharmaco logical Sciences | China | Retrospective | 2002-2012 | To discuss the effect of transplantation and the difference in treatment effect among children having different donor patterns, aiming to identify the prognostic factors |
Sano et al[21], 2021 | Frontiers in pediatrics | Japan | Retrospective | 2009-2019 | To aimed to evaluate the efficacy of T-cell replete HLA-HSCT for pediatric RR-BCP-ALL |
Paina et al[22], 2018 | Cellular Therapy and Transplantation | Germany | Prospective cohort | 2006-2016 | To assess efficiency of haplo-HSCT performed with non-manipulated grafts of children and adolescents with high-risk acute leukemias. In this respect an efficiency study of haploidentical GVHD was performed at our clinic in children and adolescents with high-risk ALL and AML, at maximal observation terms of 10 years |
Mo et al[23], 2016 | Internatio nal Journal of Cancer | China | Retrospective comparative | 2011-2015 | To compare the therapeutic effects of single UCBT and unmanipulated haplo-HSCT in high-risk ALL children |
Wang et al[24], 2020 | Journal of Internatio nal Clinical Cytometr y Society | China | Prospective cohort | 2011-2016 | To determine the impact of pre- and post-MRD status as well as peri-transplant MRD kinetics on clinical outcomes focused on children with ALL who received haploidentical allografts |
Zhang et al[25], 2022 | Chinese Medical Journal | China | Retrospective comparative | 2012-2018 | To explore the effect of allo- HSCT (especially haploidentical HSCT) on improving survival and reducing relapse for high-risk childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT |
Zheng et al[26], 2020 | Cancer Communi cations | China | Retrospective comparative | 2013-2017 | To compare the survival outcomes between high-risk AML children who underwent either unmanipulated HID-SCT or ISD-SCT at three large Chinese SCT centers |
Trujillo et al[27], 2021 | American Society For Transplan tation and Celular Therapy | Colombia | Retrospective | 2012-2017 | To decrease the toxicity associated with the addition of 100 mg/kg of cyclophosphamide to a myeloablative regimen while maintaining a good antileukemic effect and a good engraftment rate, using an intermediate-intensity regimen |
Yang et al[28], 2022 | Hematology | China | Retrospective | 2015-2021 | To investigate the outcomes and prognostic factors of pediatric AML patients with KMT2A rearrangements who were treated at our institution over a 5-year period |
Bai et al[29], 2022 | BMC cancer | China | Retrospective | 2014-2019 | To explore the role of allo- HSCT (especially haploidentical-HSCT) in the treatment of paediatric patients with MLL-r AML in CR1 and investigated the prognostic factors of these patients |
Miyamura et al[30], 2019 | Leukemia Research | Japan | Retrospective | 1988-2011 | To investigate the outcomes and prognostic factors of AML with KMT2A rearrangement treated with allogeneic HSCT |
Oevermann et al[32], 2014 | Blood | Germany | Retrospective comparative | 1996-2013 | To analyze the influence of KIR haplotypes on the outcome of children with ALL given haploidentical HSCT |
Pérez-Martínez et al[33], 2020 | American Journal of Hematolo gy | Spain | Retrospective | 1999-2016 | To compare and analyze the feasibility and outcome of a Spanish cohort of 2 haplo-HSCT platforms in children and adolescents with high-risk hematological malignancies: PT-Cy and ex vivo TCD grafts |
Ref. | All patients, n | Age, yr, median | Sex, male, n | Condition clinic | Haplo transplant cohort, n | Age, yr, median | Sex, male, n | Source of stem cells |
Kim et al[15], 2021 | 24 | 1.201 | 15 | JMML | 14 | NR | NR | PBSC |
Hong et al[16], 2022 | 80 | NR | 51 | ALL, AML, MPAL, and NK cell leukemia | 35 | 7.00 | 22 | PBSC |
Bertaina et al[17], 2018 | 343 | 3.30 | 210 | ALL, AML | 98 | 6.60 | 65 | PBSC5 BM |
Bai et al[18], 2020 | 383 | 4.00 | 25 | MLL-r B-ALL | 194 | 4.00 | 13 | NR |
Ruggeri et al[19], 2021 | 180 | 9.25 | 114 | ALL | 180 | 9.25 | 114 | PBSC BM |
Sun et al[20], 2015 | 111 | 10.00 | 73 | AML, ALL, CML, and MLL | 111 | 10.00 | 73 | PBSC BM |
Sano et al[21], 2021 | 19 | 10.00 | 12 | RR-BCP-ALL | 19 | 10.00 | 12 | PBSC, PB + BM |
Paina et al[22], 2018 | 106 | 7.00 | 65 | ALL, AML | 106 | 7.00 | 65 | BM + PBSC BM |
Mo et al[23], 2016 | 129 | NR | 42 | HR, ALL | 65 | 10.00 | 33 | G-BM, G-PB |
Wang et al[24], 2020 | 166 | 15.00 | 114 | B-ALL and T-ALL | 166 | 15.00 | 114 | NR |
Zhang et al[25], 2022 | 74 | 11.00 | 52 | HR T-ALL | 272 | 12.00 | 21 | BM |
Zheng et al[26], 2020 | 82 | NR | 56 | HR AML | 69 | 12.00 | 42 | PBSC, BM |
Trujillo et al[27], 2021 | 42 | 11.00 | 24 | ALL, AML, JMML, and CML | 42 | 11.00 | 24 | PBSC |
Yang et al[28], 2022 | 21 | NR | 15 | AML, KMT2A rearrangents | 17 | 6.06 | 12 | NR |
Bai et al[29], 2022 | 44 | 9.00 | 25 | MLL-r AML | 37 | NR | NR | NR |
Miyamura et al[30], 2019 | 90 | 3.00 | 49 | AML KMT2A rearrangents | 10 | NR | NR | NR |
Oevermann et al[32], 2014 | 85 | 10.00 | NR | ALL | 85 | 10.00 | NR | PBSC |
Pérez-Martínez et al[33], 2020 | 192 | 8.60 | 118 | ALL, AML, MDS, JMML, CML, and biphenotyipic | 192 | 8.60 | 118 | PBSC BM |
Ref. | Haplo transplant cohort, n | Conditioning regimens (all cohorts) | Haplo cohort | ||||
I | II | III | IV | EFS (%) | OS (%) | ||
Kim et al[15], 2021 | 14 | MAC: Bu-Flu | MAC: Bu-Flu-TBI | RIC: Bu-Flu-TBI | - | NRS | NRS |
Hong et al[16], 2022 | 35 | MAC, Bu, Flu | MAC, Bu, Flu, and Cy | TBI after blinatumomab | - | 74.4% (3 years) | 88.6% (3 years) |
Bertaina et al[17], 2018 | 98 | MAC: Bu | MAC/TBI: TBI-based | Treosulfan based | - | 62.0% (5 years) | 68.0% (5 years) |
Bai et al[18], 2020 | 181, 087 | MAC/chemo: Cytarabine, Cy, Bu, and semustine | - | - | - | 89.5% (4 years), NRS | 87.4% (4 years); 57.1% (4 years) |
Ruggeri et al[19], 2021 | 180 | MAC/chemo | MAC/TBI | RIC | - | 38.5%2 (2 years); 65%3; 44%4, and 18.8%5 | 50.8% (2 years); 76.5%7; 61.2%7; (NRS) |
Sun et al[20], 2015 | 111 | MAC: Bu, cycytarabine, and Me-CCNU | MAC/TBI Cy, cytarabine | - | - | 79.2% (5 years) | NR |
R | 19 | MAC: Bu, Flu, and melphalan, TBI-based | MAC: Bu-based | RIC | - | 42.1% (3 years) | 57.4% (3 years) |
Paina et al[22], 2018 | 106 | MAC: Bu, Cy, and Lomustin | MAC, Bu-flu | MAC: Treosulfan | RIC: Melphalan; RIC: Bu | NR | 33.3% (10 years); 64.7%; 18.1%, (10 years)6 |
Mo et al[23], 2016 | 65 | Cytarabine, Bu, Cy, and semustine | TBI | MAC: Bu-Flu Carmustine | MAC: CyFlu-TBI | 71% (2 years) | 82.0% (2 years) |
Wang et al[24], 2020 | 166 | RIC: Cy, MTX, MMF | - | - | - | 60.2% (100 d) | 60.8% (100 d) |
Zhang et al[25], 2022 | 23 | MAC: Bu-Cy, hydroxyurea cytarabine, and methy | - | - | - | 80.1% (5 years) | 81.0% (5 years) |
Zheng et al[26], 2020 | 69 | Bu-Cy, cytarabine, semustine | Bu-Cy-Hu, cytarabine, semustine | - | - | 72.9% (3 years) | 73.0% (3 years) |
Trujillo et al[27], 2021 | 42 | RIC: Bu-Flu-TBI | RIC: Flu-Mel-TBI | - | - | 46% (3 years) | 56% (3 years) |
Yang et al[28], 2022 | 17 | Cytarabine, Bu, and Cy Me-CCNU | Cytarabine, Bu-Cy | - | - | NRS | NRS |
Bai et al[29], 2022 | 37 | Cytarabine, Bu-Cy, and semustine | - | - | - | 65.6% (3 years) | 73.0% (3 years) |
Miyamura et al[30], 2019 | 10 | MAC, Bu-TBI | RIC, NR | - | - | NRS | NRS |
Oevermann et al[32], 2014 | 85 | TBI | Non TBI | - | - | 50.6%7 (5 years); 29.5%7 (5 years) | NR |
Pérez-Martínez et al[33] | 192 | Flu-Thiotepa-Mel or Bu | TLI or TBI | - | - | 49.2% (2 years) | 55.1% (2 years) |
- Citation: Cardoso Brito ACC, Oliveira Carneiro Ribeiro E, Freire de Melo F. Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias. World J Meta-Anal 2023; 11(5): 181-195
- URL: https://www.wjgnet.com/2308-3840/full/v11/i5/181.htm
- DOI: https://dx.doi.org/10.13105/wjma.v11.i5.181